What Is TB-500?
TB-500 is a synthetic peptide corresponding to the amino acid sequence 17–23 of Thymosin Beta-4 (Tβ4) — a naturally occurring 43-amino acid protein found throughout mammalian tissue. The fragment is: Ac-LKKTETQ (sometimes written as the 4-amino acid core: LKKT or the extended actin-binding domain).
Thymosin Beta-4 itself is an endogenous peptide present at significant concentrations in platelets, macrophages, wound fluid, and most cell types. It plays a fundamental role in actin sequestration and cell motility — two processes central to wound healing and tissue remodeling.
TB-500 should be understood as a fragment that captures a subset of Tβ4’s biological activity, specifically the actin-binding domain that mediates many of its repair-promoting effects.
Biological Role of Thymosin Beta-4
Thymosin Beta-4 was first identified in 1965 by Allan Goldstein at the Albert Einstein College of Medicine, originally characterized as a thymic hormone influencing T-cell development. Its roles have since expanded substantially:
Actin Dynamics and Cell Migration
The primary known function of Tβ4 is sequestration of G-actin (globular actin monomers). It binds actin in a 1:1 ratio, maintaining the pool of soluble actin available for rapid cytoskeletal reorganization. This is mechanistically important for:
- Fibroblast migration into wound beds
- Epithelial cell mobilization during re-epithelialization
- Macrophage and immune cell movement to sites of injury
- Endothelial cell migration during angiogenesis
Cell movement is fundamentally dependent on actin polymerization at the leading edge; Tβ4 regulates the size and availability of the actin monomer pool that enables this.
Angiogenesis
Tβ4 is one of the most potent angiogenic peptides identified. It promotes new blood vessel formation through:
- Upregulation of VEGF and its receptors
- Direct stimulation of endothelial cell migration
- Promotion of smooth muscle cell differentiation
In ischemic tissue models, Tβ4 administration increases capillary density and restores perfusion — making it an active area of research for cardiac and peripheral vascular disease.
Anti-Inflammatory Effects
Tβ4 reduces pro-inflammatory cytokine production, particularly through NF-κB pathway modulation. In wound models, this translates to faster transition from the inflammatory phase to the proliferative phase of healing.
Cardioprotection
One of the most actively researched areas: Tβ4 appears to promote survival of cardiac progenitor cells after ischemic injury and may stimulate limited cardiomyocyte regeneration in rodent models.
TB-500 vs Thymosin Beta-4: A Critical Distinction
This distinction is frequently blurred in research chemical communities, and it matters.
Thymosin Beta-4 (Tβ4) is the full 43-amino acid endogenous protein. It is undergoing clinical trials (see below).
TB-500 is a specific fragment — the 17-23 sequence — chosen because it contains the actin-binding domain and is believed to be responsible for many of Tβ4’s repair-promoting effects. However, it is not the same molecule.
Studies specifically on the TB-500 fragment are limited compared to the body of Tβ4 research. When research community members cite “TB-500 studies,” they are often citing full Tβ4 research and assuming the fragment replicates the parent molecule’s effects — an assumption not fully validated.
Human Clinical Trials: Thymosin Beta-4
Unlike most research peptides, Thymosin Beta-4 (the full protein, not TB-500 fragment) has undergone Phase 1 and Phase 2 human trials, primarily in cardiovascular indications.
CHAMP Trial (Cardiac)
- Sponsor: RegeneRx Biopharmaceuticals
- Indication: Acute myocardial infarction
- Design: Phase 2, randomized, double-blind
- Result: No significant benefit on primary endpoint (infarct size by MRI) in the 2014 publication, though some favorable trends in secondary endpoints
- Dose used: 1,050 mg IV — orders of magnitude higher than typical TB-500 self-experimentation doses
REACH Trial (Peripheral Vascular Disease)
- Indication: Lower extremity ischemia
- Status: Completed Phase 2; results showed significant improvement in pain-free walking distance
- Significance: This is one of the better pieces of human evidence for Tβ4 efficacy
Wound Healing
- Phase 1/2 trials in pressure ulcers and venous stasis ulcers showed accelerated healing vs placebo
Important note: These trials used intravenous or topical Tβ4, not subcutaneous TB-500 fragment, and at doses that cannot be translated to TB-500 protocols.
Animal Evidence Summary
The preclinical literature on Tβ4 and TB-500 is extensive:
Cardiac
- Restoration of cardiac function in mouse models of MI
- Reduction in infarct size
- Promotion of cardiac stem cell mobilization
Wound Healing
- Accelerated closure of excisional wounds in rodents
- Improved re-epithelialization
- Enhanced collagen organization
CNS
- Promotion of oligodendrocyte differentiation and remyelination in mouse models of multiple sclerosis
- Neuroprotection following traumatic brain injury
- Ongoing research into Parkinson’s disease models
Muscle and Tendon
- Accelerated muscle fiber regeneration after cardiotoxin-induced injury
- Enhanced tendon cell (tenocyte) proliferation and collagen synthesis
Pharmacokinetics
TB-500 fragment pharmacokinetics have not been formally characterized in humans. What is known from Tβ4 studies:
- Tβ4 distributes widely to tissues after injection
- Plasma half-life is short (minutes to low hours for the endogenous protein)
- The synthetic TB-500 fragment may have different degradation kinetics due to its smaller size
- No human bioavailability studies have been published for subcutaneous TB-500
Safety Considerations
For full Tβ4 in clinical trials: The human trial record shows a generally acceptable safety profile at the doses tested (up to 1,050 mg IV). No dose-limiting toxicities were identified in Phase 1 studies.
For TB-500 fragment specifically: No formal human safety data exists.
Theoretical concerns:
- Angiogenesis in malignancy: As with BPC-157, promotion of angiogenesis is a theoretical concern in the context of existing solid tumors
- Immune modulation: Tβ4’s effects on T-cell development and macrophage function could have implications for autoimmune conditions or immunocompromised individuals
- Cardiac remodeling: While cardioprotective in ischemia, the effects of chronic Tβ4/TB-500 administration on a healthy heart are unknown
Regulatory Status
TB-500 (the fragment) has no regulatory approval anywhere. It is sold as a research chemical.
Thymosin Beta-4 products (including some topical preparations) have reached various stages of regulatory review. RegeneRx holds patents on Tβ4 and its derivatives.
WADA added Thymosin Beta-4 and its fragments to the prohibited list in 2012. TB-500 is explicitly prohibited in competitive sport.
Comparison with BPC-157
These two peptides are frequently discussed together in healing/recovery contexts and are sometimes “stacked” in self-experimentation protocols:
| Parameter | TB-500 | BPC-157 |
|---|---|---|
| Source | Endogenous (Tβ4 fragment) | Synthetic (gastric protein fragment) |
| Primary mechanism | Actin dynamics, angiogenesis | NO pathway, VEGF, growth factor upregulation |
| Cardiac evidence | Phase 2 human trials (Tβ4) | Animal only |
| Best-supported use | Angiogenesis, wound healing | Tendon, gut, nerve (animal) |
| Human safety data | Limited (Tβ4, IV) | None |
Bottom Line
TB-500 sits in an interesting intermediate position: the parent molecule (Tβ4) has more human clinical trial data than most research peptides — including Phase 2 cardiovascular trials. This creates some inferential basis for the biology.
However, TB-500 specifically is a fragment that has been studied much less thoroughly, used at doses incomparable to the trial data, and administered via routes (subcutaneous injection) that differ from the trial protocols (IV or topical).
The gap between “Tβ4 showed meaningful results in a Phase 2 trial for peripheral vascular disease” and “subcutaneous TB-500 at typical self-experimentation doses will accelerate tendon recovery” is a substantial inferential leap that the evidence does not directly support.
The biology is credible. The translation to practice is extrapolation.
This guide is for educational purposes only. TB-500 is not approved for human therapeutic use. Consult a physician before considering any peptide protocol.
Found this useful? Share it with someone who'd benefit.